Norovirus Infection

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Vaxart
VaxartSOUTH SAN FRANCISCO, CA
2 programs
2
Norwalk GI.1 VirusPhase 11 trial
VXA-G1.1-NNPhase 11 trial
Active Trials
NCT03721549CompletedEst. Nov 2018
NCT03897309CompletedEst. Apr 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
VaxartVXA-G1.1-NN
VaxartNorwalk GI.1 Virus

Clinical Trials (2)

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines

Start: Mar 2019Est. completion: Apr 2021
Phase 1Completed
NCT03721549VaxartNorwalk GI.1 Virus

Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model

Start: Oct 2018Est. completion: Nov 2018
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space